

# **The Role of Neutrophils, Lymphocytes and Monocytes in Ischemic Heart Disease: Friend or Foe?**

## **Abstract**

Ischemic heart disease (IHD) remains a leading cause of morbidity and mortality globally. In recent years research has increasingly focused on the interplay between the white blood cells and the development and progression of IHD. Neutrophils, lymphocytes, and Monocytes play an important role in the immune system and were found to have dual roles in both protective mechanisms and harmful effects. Neutrophils are traditionally viewed as first responders to tissue injury. Their rapid infiltration aids in the clearance of cellular debris and pathogens, while the release of reactive oxygen species and inflammatory mediators can exacerbate tissue damage. Additionally, neutrophils participate in intercommunication with endothelial cells and platelets, influencing the progression of atherosclerosis and thrombosis. Lymphocytes, a key player in adaptive immune response, similarly exhibit a dual role in IHD. Their involvement extends beyond immune surveillance. Monocytes contribute to phagocytosis and tissue repair while some of their actions cause atherosclerotic plaque instability. This review provides an overview of IHD, covering its prevalence, pathogenesis, risk factors, clinical manifestations, diagnosis, and the involvement of white blood cells, including neutrophils, lymphocytes, and monocytes, in the disease process.

Keywords: Ischemic heart disease, white blood cells, neutrophils, lymphocytes, monocytes.

## **Introduction**


Ischemia can be described as reduced blood flow (circulation) to a particular organ due to obstruction of blood vessels supplying that area[1]. Ischemic heart disease (IHD), commonly known as coronary artery disease (CAD) or coronary heart disease, stands as a prevailing and formidable global health challenge[2,3,4]. Characterized by an impaired blood supply to the myocardium, IHD results from the progressive narrowing or complete occlusion of coronary arteries, typically due to the formation of plaque, called atherosclerosis. This vascular condition leads to an inadequate delivery of oxygen and nutrients to the heart muscle, instigating a cascade of events that profoundly impact cardiovascular function[5].

Globally, around 620 million people deal with heart and circulatory disorders. On a global scale, it is estimated that one in every thirteen persons has a heart or circulatory disorder. The most prevalent cardiovascular disorder is ischemic heart disease with a global prevalence indicated at 200 million in 2019 with 9.14 million deaths[6,7]. The significance of IHD lies not only in its prevalence but also in its repercussions on public health and individual well-being. According to the World Health Organization (WHO), IHD remains the leading cause of death worldwide, accounting for a prevalence rate of 3820 cases per 100,000 population worldwide. Its pervasive nature transcends geographical boundaries, affecting individuals across diverse demographics and socioeconomic strata[8,9]. Cardiovascular disease is the leading cause of death in Asia, and it is considered a growing epidemic. In 2019, 10.8 million people died from heart and circulatory disorders, the majority of which were caused by ischemic heart disease (47%), accounting for approximately 35% of all deaths in the Asian continent[10]. In Sri Lanka, coronary heart disease deaths were reported as 26,304, or 22.66% of all deaths in 2020 [11, 12].

According to a study conducted in 2005, the prevalence of IHD in Sri Lanka was found to be 9.3%, with a higher prevalence among females (11.3%) compared to males (7.2%)[13].

### Pathogenesis of IHD

The pathogenesis of IHD is intricately linked to atherosclerosis, a chronic inflammatory process characterized by the deposition of cholesterol, lipids, and cellular debris within the coronary arteries. Over time, these atherosclerotic plaques can undergo rupture or erosion, triggering thrombotic events that further compromise blood flow to the heart muscle[5,14]. The clinical manifestations of IHD encompass a spectrum of conditions, ranging from stable angina to acute coronary syndromes such as myocardial infarction, each posing distinct challenges in terms of diagnosis, management, and prevention.



**Figure 1:** Mechanisms of pathophysiology in ischemic heart disease. Adapted from [15].

IHD is linked to Inflammation, Atherosclerosis, Vasospasm, and coronary microvascular dysfunction (Figure 1). Risk factors of atherosclerosis such as aging, diabetes mellites, arterial hypertension, dyslipidemia, genetic predisposition, and smoking contribute to the progression of plaque development and eventually lead to CAD or Angina. Prolonged or sudden severe obstructions can cause Acute Myocardial Infarction (AMI). Tumor Necrosis Factor-alpha, C-reactive protein, Neutrophils, and Interleukins (IL-6R) collectively contribute to the local inflammatory response during AMI. Stenosis marks the advanced and ultimate phase of the intricate atherosclerotic progression. In IHD, apart from the local inflammation, systemic inflammation also takes place releasing cytokines, Angiotensin II, and triggering oxidative stress.

This will lead to endothelial dysfunction and eventually deregulated excessive inflammation. Vasospasms refer to sudden, intense contractions of the coronary arteries. These spasms can lead to temporary narrowing or complete closure of the vessels leading to IHD. Coronary microvascular dysfunction (CMD) involves structural and functional changes in the small blood vessels (microcirculation) within the heart. It affects the arterioles and capillaries that regulate blood flow. CMD can impair coronary autoregulation, leading to inadequate blood supply to the heart muscle. Endothelial dysfunction, risk factors like hypertension, diabetes mellitus, Myocardial Infarction with Non-Obstructive Coronary Artery Disease (MINOCA), Ischemia and No Obstructive Coronary Artery Disease (INOCA), cardiotropic viruses increase CMD risk. On the other hand, CMD can worsen the ischemia-reperfusion injury (IRI): i.e. blood flow to an organ (such as the heart) is temporarily interrupted (ischemia) and then restored (reperfusion). This can lead to microvascular injury worsening the outcomes in patients with IRI [15].

### **Risk factors of IHD**

IHD encompasses a range of conditions caused by reduced blood flow to the heart muscle, often due to coronary artery disease. Several risk factors contribute to its development, including age, gender, hypertension, smoking, particulate matter pollution, diabetes, unhealthy dietary habits, overweight, physical inactivity, and a family history of IHD. These factors can lead to the buildup of plaque in the arteries, restricting blood flow and oxygen delivery to the heart [16,17,18]. According to findings from a study conducted at the Teaching Hospital Peradeniya in Sri Lanka, there is evidence suggesting a progressive development of ischemic heart disease in association with smoking and alcohol consumption [19]. A study conducted at the Teaching Hospital Jaffna in Sri Lanka found evidence that physical inactivity, unhealthy dietary habits, alcoholism, and smoking are lifestyle risk factors among patients with Ischemic Heart Disease IHD[20].

### **Signs and symptoms of IHD**

The signs and symptoms of ischemic heart disease occur when the heart does not get sufficient amounts of oxygenated blood[21]. Symptoms of IHD vary but commonly include chest pain or discomfort (angina), shortness of breath, fatigue, nausea, and sweating. However, some individuals, particularly women and older adults, may experience atypical symptoms or no symptoms at all, complicating diagnosis. In severe cases, ischemic heart disease can lead to a myocardial infarction or sudden cardiac death[22, 23]. Early recognition of risk factors, regular monitoring, and prompt medical intervention are essential for managing IHD and reducing the risk of complications.

### **Diagnosis of IHD**

Accurate and timely diagnosis is paramount in the effective management of IHD. The diagnostic process for IHD involves a comprehensive clinical assessment and patient history, imaging techniques, and laboratory tests. Clinicians utilize a combination of these tools to not only confirm the presence of IHD but also to determine its severity, guide appropriate interventions, and mitigate the risk of complications[22, 23]. In clinical evaluation, healthcare professionals gather information about a patient's medical history, risk factors, and presenting symptoms which were formerly discussed.

Various imaging techniques play a crucial role in diagnosing IHD and evaluating its impact on cardiac function. Non-invasive imaging modalities include electrocardiography (ECG or EKG), stress testing (exercise or pharmacological), echocardiography, and nuclear imaging. ECG provides valuable information about the heart's electrical activity, helping identify abnormalities indicative of ischemia or previous heart damage. Stress testing involves monitoring the heart's response to physical or pharmacological stress, revealing changes that may not be apparent at rest. Echocardiography uses ultrasound to assess cardiac structure and function, while nuclear imaging provides detailed information about blood flow to the heart muscle[24].

Laboratory tests contribute to the diagnosis of IHD by assessing cardiac biomarkers. Troponins (T or I), creatine phosphokinase-MB (CK-MB), and myoglobin are commonly measured to detect myocardial damage[25, 26]. Ischemia modified albumin (IMA), Brain natriuretic peptide (BNP), and N-terminal pro b-type natriuretic peptide (NT-proBNP), ST2, copeptin, galectin-3, Whole Blood Choline, Unesterified Free Fatty Acids are some of the markers of ischemia where elevated levels of these biomarkers suggest ongoing or recent cardiac injury or ischemia [27, 28]. Additionally, lipid profile assessments aid in evaluating cardiovascular risk by measuring cholesterol levels[29].

Invasive procedures, such as coronary angiography, provide a direct visualization of the coronary arteries. This procedure involves injecting contrast dye into the coronary arteries, allowing for the identification of blockages or narrowed segments. Coronary angiography is often performed in conjunction with percutaneous coronary intervention (PCI), commonly known as angioplasty, to open narrowed arteries and restore blood flow[30, 31].

### ***Hematological parameters***

Hematological parameters, which encompass a variety of blood components and characteristics, can provide valuable information in the diagnosis and management of IHD. While these parameters are not specific to IHD, certain hematological markers can offer insights into the underlying pathophysiological processes and contribute to risk assessment.

#### **Complete Blood Count (CBC)**

CBC provides information about the cellular components of the blood, including red blood cells (RBCs), white blood cells (WBCs), and platelets. Abnormalities in the CBC, such as anemia or elevated platelet count, may suggest underlying conditions that can contribute to or result from IHD[32, 33].

#### **Hemoglobin and Hematocrit**

Hemoglobin, a globin which has a tetrameric structure primarily transport oxygen throughout the body. Hematocrit is a measurement that indicates the proportion of red blood cells in relation to the total volume of blood [34]. Both parameters in the CBC are crucial indicators of anemia a condition where the number of red blood cells or the quantity of hemoglobin in the blood get reduced, leading to a reduced capacity of blood to carry oxygen to tissues and organs throughout the body [35]. Reduce the oxygen-carrying capacity of the blood, cause ischemia in individuals with IHD. Therefore, monitoring hemoglobin levels and the hematocrit is important in IHD. Also, it is relevant in assessing oxygen supply-demand imbalances[32].

#### **Red Cell Distribution Width (RDW)**

RDW is a measure of the variation in size (size heterogeneity) of red blood cells, derived by dividing the standard deviation (SD) of erythrocyte volumes by the mean corpuscular volume (MCV). Elevated RDW has been associated with increased mortality in cardiovascular diseases, including IHD (Normal range 80-100 fL). It can serve as a marker of underlying systemic inflammation, and oxidative stress[32, 33,36,37].

#### Platelet Count and Mean Platelet Volume (MPV)

Platelets play a key role in blood clotting, and abnormalities in platelet count or function can contribute to thrombotic events in IHD. Elevated platelet counts or increased platelet reactivity may increase the risk of clot formation in the coronary arteries[32,38].MPV is a measure of the average size of platelets. Increased MPV has been associated with increased platelet activity and may indicate a prothrombotic state, potentially contributing to the risk of coronary events[38]. Recent studies suggest that larger platelets exhibit increased enzymatic and metabolic activity, contributing to their higher thrombotic potential compared to smaller platelets. Large platelets have a greater surface area relative to their volume, providing more sites for receptor binding and aggregation. This increased surface area facilitates enhanced interactions with various prothrombotic factors, such as von Willebrand factor and fibrinogen, leading to more efficient platelet activation and clot formation. Additionally, larger platelets tend to contain higher concentrations of granules, which store bioactive molecules involved in platelet activation and aggregation, further amplifying their thrombotic ability. Moreover, larger platelets have been shown to express higher levels of glycoprotein receptors, particularly GPIIb/IIIa, which play a crucial role in platelet adhesion and aggregation during thrombus formation [33, 39, 40].

#### Fibrinogen

Fibrinogen is a key factor in blood clot formation. Elevated fibrinogen levels have been associated with increased cardiovascular risk and may contribute to the formation of thrombi in coronary arteries. The elevation of  $\gamma A/\gamma'$  isoform of fibrinogen in CAD, myocardial infarction, and ischemic stroke was evident [41].

#### D-dimer

D-dimer is a marker of fibrinolysis and is often elevated in conditions associated with increased blood clot formation and breakdown. Elevated D-dimer levels may indicate ongoing thrombus formation in the coronary arteries[42]. Furthermore, studies have shown that D-dimer level is directly related to the occurrence and recurrence of cardiovascular diseases[42].

#### White Blood Cell Count (WBC)

White blood cells, which include neutrophils, lymphocytes, monocytes, eosinophils, and basophils, play important functions in the pathogenesis of atherosclerosis. Neutrophils, the most abundant type of WBC, contribute to the initial inflammatory response in atherosclerotic lesions, increasing inflammation and causing tissue damage [33, 44]. Lymphocytes, which include B and T cells, contribute to the adaptive immune response during atherosclerosis, altering plaque stability and progression [45]. Monocytes recruited to the arterial wall differentiate into macrophages, which are essential in plaque formation and progression by promoting foam cell formation and producing inflammatory mediators [46]. Although less studied, eosinophils and basophils may contribute to atherosclerosis through their involvement in allergic and inflammatory responses [47]. Inflammatory cytokines and chemokines released by WBCs

regulate leukocyte recruitment and activation within plaques, influencing plaque stability and the risk of rupture [48].

### Neutrophils

Neutrophils, a type of white blood cell, stand as frontline defenders within the immune system, playing a pivotal role in the body's response to infection and inflammation[33, 49]. Characterized by a multi-lobed nucleus and a granular cytoplasm, neutrophils are highly mobile and adept at migrating towards sites of infection or tissue damage. Upon arrival at the scene, they engage in phagocytosis, engulfing and digesting pathogens or foreign particles[50]. Neutrophils contain antimicrobial proteins and enzymes stored in their granules, allowing them to neutralize and eradicate invading microorganisms efficiently. While primarily recognized for their role in the innate immune response, recent research has revealed the involvement of neutrophils in various physiological and pathological processes, extending beyond infection control[51].

### Lymphocytes

Lymphocytes are a type of white blood cell crucial for the adaptive immune system, playing a pivotal role in recognizing and combating pathogens and foreign substances[51]. They originate from stem cells in the bone marrow and mature into T lymphocytes(T cells), B lymphocytes (B cells), or natural killer (NK) cells. T cells are responsible for cell-mediated immunity, coordinating immune responses and directly attacking infected or abnormal cells. B cells produce antibodies, specialized proteins that target and neutralize specific pathogens or toxins. NK cells are cytotoxic lymphocytes that recognize and eliminate cells that have been infected or transformed, such as cancerous cells. Lymphocytes are essential for maintaining immune surveillance and memory, providing long-term protection against recurrent infections and diseases[33, 53, 54, 55].

### Monocytes

Monocytes, a vital component of the immune system, are a type of white blood cell with a crucial role in both innate and adaptive immunity. Characterized by a kidney-shaped nucleus and a gray-blue cytoplasm, monocytes circulate in the bloodstream, surveying for signs of infection, inflammation, or tissue damage[56]. Upon encountering a stimulus, such as pathogens or damaged cells, monocytes migrate to the affected site and undergo differentiation into macrophages or dendritic cells[57]. Macrophages, derived from monocytes, are versatile phagocytic cells with a capacity for antigen presentation, contributing to the initiation of specific immune responses. Monocytes also play a significant role in tissue repair and remodeling, contributing to the resolution of inflammation and the maintenance of homeostasis[58].

### **Role of Neutrophils in IHD**

Neutrophils, once viewed solely as frontline defenders against infection, are now recognized as key players in the inflammatory processes underlying IHD. Atherosclerosis, a primary contributor to IHD, involves a complex interplay of inflammatory responses wherein neutrophils assume a pivotal role. These immune cells are recruited to the vascular endothelium in response to inflammatory stimuli, where they adhere and migrate into the subendothelial space, releasing pro-inflammatory cytokines, reactive oxygen species (ROS), and enzymes. This cascade of events contributes to endothelial dysfunction, oxidative stress, and vascular damage [59]. Additionally, neutrophils engage in interactions with platelets, fostering thrombus formation, a

critical event in acute coronary syndromes [60, 61]. Furthermore, their presence within atherosclerotic plaques can destabilize them, increasing the risk of rupture and subsequent thrombosis leading to myocardial infarction [62]. Moreover, neutrophils release extracellular traps, which exacerbate endothelial dysfunction, plaque destabilization, and thrombosis, further perpetuating IHD progression [63]. Neutrophil-mediated oxidative stress, through the generation of ROS, overwhelms endogenous antioxidant defences, contributing to lipid peroxidation and vascular inflammation characteristic of IHD [64]. Additionally, their secretion of matrix metalloproteinases facilitates plaque destabilization by degrading extracellular matrix components, increasing the risk of rupture and thrombosis [65]. Given the multifaceted involvement of neutrophils in IHD pathophysiology, targeting their recruitment, activation, or effector functions may hold promise for therapeutic intervention, potentially reducing cardiovascular events [66].

### **Role of Lymphocytes in IHD**

In IHD, lymphocytes contribute significantly to the inflammatory response within the arterial walls. T cells are involved in the immune reactions in IHD. Upon activation, T cells migrate to the site of arterial injury, where they release inflammatory cytokines and interact with other immune cells, exacerbating the inflammatory cascade[67]. Additionally, B cells may play a role in IHD by producing antibodies that recognize and bind to antigens present in atherosclerotic plaques, potentially contributing to plaque destabilization and rupture[68]. While the precise mechanisms by which lymphocytes contribute to IHD pathology are still being studied, their role highlights the relationship between the immune system and cardiovascular diseases.

Additionally, a lower lymphocyte count has been identified as a promising prognostic indicator for acute coronary syndrome and stable ischemic heart disease, showing a significant correlation with extended survival among patients with IHD [69, 70].

### **Role of Monocytes in IHD**

Monocytes play an important role in the pathophysiology of IHD, particularly in the context of atherosclerosis and its complications. Atherosclerosis, a chronic inflammatory condition involving the deposition of lipids and immune cells in arterial walls [71]. Monocytes are central players in the immune response during atherosclerosis, contributing to the formation and progression of atherosclerotic plaques[72]. Monocytes are recruited to the site of vascular injury or inflammation in response to chemotactic signals. Once at the scene, they adhere to the endothelium and transmigrate into the subendothelial space. Within the vessel wall, monocytes undergo differentiation into macrophages, which become key contributors to plaque formation. Activated macrophages within the arterial wall engulf oxidized low-density lipoproteins, transforming into foam cells. The accumulation of foam cells is a characteristic feature of early atherosclerotic lesions. The lipid-laden foam cells contribute to the formation of fatty streaks, which are precursors to more advanced atherosclerotic plaques. Macrophages and monocytes release pro-inflammatory cytokines and chemokines, fostering a local inflammatory environment within the arterial wall [73]. These inflammatory mediators contribute to the recruitment of additional immune cells and exacerbate the inflammatory response, further promoting atherosclerosis[74, 75].

Furthermore, Monocytes and macrophages play a crucial role in the destabilization of atherosclerotic plaques. Their presence contributes to the thinning of the fibrous cap covering the

plaque, making it more susceptible to rupture. Plaque rupture exposes thrombogenic material, triggering platelet aggregation and thrombus formation, which can lead to acute cardiovascular events such as myocardial infarction [76].

### **Future directions**

The investigation of neutrophils, lymphocytes, and monocytes in IHD represents a dynamic research area where future directions hold great promise for improving our understanding and therapeutic approaches. Examining the complex roles played by these immune cells in various IHD subtypes, such as acute myocardial infarction, unstable angina, and stable angina, may provide an understanding on how these cells change as atherosclerosis develops. Furthermore, studies examining the ways in which common comorbidities such as diabetes, hypertension, and obesity influence neutrophil, lymphocyte, and monocyte behaviors in the context of IHD represent essential research directions. We may be able to identify new therapeutic targets and approaches for addressing the complicated relationship between these factors and IHD.

### **Conclusion**

In conclusion, the important role of neutrophils, lymphocytes and monocytes in IHD reveals a complex narrative where these immune cells, traditionally considered defenders of the body, can manifest as both friends and foes. While these cells are crucial in the immune response against pathogens, their involvement in the inflammatory processes of atherosclerosis and subsequent plaque destabilization poses significant challenges in the context of cardiovascular health. The delicate balance between protective and harmful effects of neutrophils, lymphocytes and monocytes in IHD shows the need for a better understanding of their roles. This review has attempted to explain the comprehensive contributions of these white blood cells in various stages of IHD, from the initiation of atherosclerotic lesions to the critical events leading to acute cardiovascular events.

### **Authors' contributions**

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

### **References**

1. Institute of Medicine (US) Committee on Social Security Cardiovascular Disability Criteria (2010). Ischemic Heart Disease. [online] Nih.gov. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK209964/>
2. Khan MA, Hashim MJ, Mustafa H, Baniyas MY, Al Suwaidi SKBM, AlKatheeri R, et al. Global Epidemiology of Ischemic Heart Disease: Results from the Global Burden of Disease Study. Cureus [Internet]. 2020 Jul 23 [cited 2022 Nov 30]; Available from: <https://www.cureus.com/articles/36728-global-epidemiology-of-ischemic-heart-disease-results-from-the-global-burden-of-disease-study>
3. Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G, et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. J Am CollCardiol. 2017 Jul 4;70(1):1–25.

4. Zhang L, Tong Z, Han R, Guo R, Zang S, Zhang X, et al. Global, Regional, and National Burdens of Ischemic Heart Disease Attributable to Smoking From 1990 to 2019. *J Am Heart Assoc.* 2023 Feb 7;12(3):e028193.
5. Criteria I of M (US) C on SSCD. Ischemic Heart Disease. In: *Cardiovascular Disability: Updating the Social Security Listings* [Internet]. National Academies Press (US); 2010 [cited 2024 Feb 12]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK209964/>
6. British Heart Foundation (2023). *Global Heart & Circulatory Diseases Factsheet*. [online] Available at: <https://www.bhf.org.uk/-/media/files/for-professionals/research/heart-statistics/bhf-cvd-statistics-global-factsheet.pdf>.
7. Wu, P., Yu, S., Wang, J., Zou, S., Yao, D.-S. and Yuan, X. (2023). Global burden, trends, and inequalities of ischemic heart disease among young adults from 1990 to 2019: a population-based study. *Frontiers in Cardiovascular Medicine*, 10. doi:<https://doi.org/10.3389/fcvm.2023.1274663>.
8. Cardiovascular diseases (CVDs) [Internet]. [cited 2023 Apr 8]. Available from: [https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-\(cvds\)](https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds))
9. *Epidemiology of Ischemic Heart Disease* | SpringerLink [Internet]. [cited 2024 Feb 12]. Available from: [https://link.springer.com/chapter/10.1007/978-3-031-25879-4\\_6](https://link.springer.com/chapter/10.1007/978-3-031-25879-4_6)
10. Zhao, D. (2021). Epidemiological Features of Cardiovascular Disease in Asia. *JACC: Asia*, 1(1), pp.1–13. doi:<https://doi.org/10.1016/j.jacasi.2021.04.007>.
11. World Life Expectancy [Internet]. [cited 2024 Feb 12]. Coronary Heart Disease in Sri Lanka. Available from: <https://www.worldlifeexpectancy.com/sri-lanka-coronary-heart-disease>
12. Sri Lanka | Cadi [Internet]. [cited 2024 Feb 12]. Available from: <https://cadiresearch.org/topic/asian-indian-heart-disease/cadi-sri-lanka>
13. Katulanda P, Liyanage IK, Caldera R, Constantine GR, Sheriff MHR, Matthews DR. Prevalence of ischaemic heart disease and risk factors in Sri Lanka. 2010 [cited 2024 Feb 12]; Available from: <http://archive.cmb.ac.lk:8080/research/handle/70130/1944>
14. *IJMS | Free Full-Text | Ischemic Heart Disease Pathophysiology Paradigms Overview: From Plaque Activation to Microvascular Dysfunction* [Internet]. [cited 2024 Feb 12]. Available from: <https://www.mdpi.com/1422-0067/21/21/8118>.
15. Severino, P., D'Amato, A., Pucci, M., Infusino, F., Adamo, F., Birtolo, L.I., Netti, L., Montefusco, G., Chimenti, C., Lavallo, C., Maestrini, V., Mancone, M., Chilian, W.M. and Fedele, F. (2020). Ischemic Heart Disease Pathophysiology Paradigms Overview: From Plaque Activation to Microvascular Dysfunction. *International Journal of Molecular Sciences*, 21(21). doi:<https://doi.org/10.3390/ijms21218118>.
16. Brown JC, Gerhardt TE, Kwon E. Risk Factors for Coronary Artery Disease. In: *StatPearls* [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Feb 12]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK554410/>
17. Shu, T., Tang, M., He, B., Liu, X., Han, Y., Liu, C., Jose, P.A., Wang, H., Zhang, Q.-W. and Zeng, C. (2024). Assessing Global, Regional, and National Time Trends and Associated Risk Factors of the Mortality in Ischemic Heart Disease Through Global Burden of Disease 2019

Study: Population-Based Study. JMIR Public Health and Surveillance, [online] 10(1), p.e46821. doi:<https://doi.org/10.2196/46821>.

18. Chang, M., Hahn, R.A., Teutsch, S.M. and Hutwagner, L.C. (2001). Multiple risk factors and population attributable risk for ischemic heart disease mortality in the United States, 1971–1992. *Journal of Clinical Epidemiology*, 54(6), pp.634–644. doi:[https://doi.org/10.1016/s0895-4356\(00\)00343-7](https://doi.org/10.1016/s0895-4356(00)00343-7).
19. Ralapanawa U, Kumarasiri PVR, Jayawickreme KP, Kumarihamy P, Wijeratne Y, Ekanayake M, et al. Epidemiology and risk factors of patients with types of acute coronary syndrome presenting to a tertiary care hospital in Sri Lanka. *BMC CardiovascDisord*. 2019 Dec;19(1):229.
20. Sivajenani, S., Kuillini, S. and Madona, E., 2015. Lifestyle factors influencing coronary heart disease.
21. Mayo Clinic (2022). Coronary Artery Disease . [online] Mayo Clinic. Available at: <https://www.mayoclinic.org/diseases-conditions/coronary-artery-disease/symptoms-causes/syc-20350613>.
22. CDC. Centers for Disease Control and Prevention. 2021 [cited 2024 Feb 12]. Coronary Artery Disease | cdc.gov. Available from: [https://www.cdc.gov/heartdisease/coronary\\_ad.htm](https://www.cdc.gov/heartdisease/coronary_ad.htm)
23. nhs.uk [Internet]. 2018 [cited 2023 Feb 21]. Coronary heart disease - Symptoms. Available from: <https://www.nhs.uk/conditions/coronary-heart-disease/symptoms/>
24. JCDD | Free Full-Text | Multimodality Imaging in the Detection of Ischemic Heart Disease in Women [Internet]. [cited 2024 Feb 12]. Available from: <https://www.mdpi.com/2308-3425/9/10/350>
25. C. D. Biomarkers of Cardiac Ischemia. In: Gaze D, editor. Ischemic Heart Disease [Internet]. InTech; 2013 [cited 2022 Oct 9]. Available from: <http://www.intechopen.com/books/ischemic-heart-disease/biomarkers-of-cardiac-ischemia>
26. Vasan RS. Biomarkers of Cardiovascular Disease. *Circulation*. 2006 May 16;113(19):2335–62.
27. American College of Cardiology [Internet]. [cited 2024 Feb 12]. What Biomarkers Are Useful for Detection of Myocardial Ischemia? Available from: <https://www.acc.org/Latest-in-Cardiology/Articles/2014/07/18/14/24/http%3a%2f%2fwww.acc.org%2fLatest-in-Cardiology%2fArticles%2f2014%2f07%2f18%2f14%2f24%2fWhat-Biomarkers-Are-Useful-for-Detection-of-Myocardial-Ischemia>
28. Dhingra, R. and Vasan, R.S. (2017). Biomarkers in cardiovascular disease: Statistical assessment and section on key novel heart failure biomarkers. *Trends in Cardiovascular Medicine*, 27(2), pp.123–133. doi:<https://doi.org/10.1016/j.tcm.2016.07.005>
29. [Lipid profile and risk factors for cardiovascular diseases in medicine students] - PubMed [Internet]. [cited 2023 Jul 30]. Available from: <https://pubmed.ncbi.nlm.nih.gov/16041456/>
30. Overview - Cardiovascular Disability - NCBI Bookshelf [Internet]. 2010 [cited 2022 May 22]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK209971/#ddd00024>

31. Mickley H. [Coronary arteriography and coronary angioplasty in stable ischemic heart disease. Value in the prediction and prevention of future acute myocardial infarction]. *UgeskrLaeger*. 1999 Sep 13;161(37):5146–51.
32. Seo IH, Lee YJ. Usefulness of Complete Blood Count (CBC) to Assess Cardiovascular and Metabolic Diseases in Clinical Settings: A Comprehensive Literature Review. *Biomedicines*. 2022 Nov;10(11):2697.
33. Nuwanthika WKT, Welivitigoda DIK, Senadeera SPNN, Kottahachchi DU, Ranaweera CB, Wijesighe N. Role Played by Biochemical and Hematological Parameters in the Prediction of Cardiovascular Risk. *AJRB*. 2024 Mar 11;14(2):7–17.10.9734/AJRB/2024/v14i2278
34. Billett HH. Hemoglobin and Hematocrit. In: Walker HK, Hall WD, Hurst JW, editors. *Clinical Methods: The History, Physical, and Laboratory Examinations* [Internet]. 3rd ed. Boston: Butterworths; 1990 [cited 2024 Feb 12]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK259/>
35. Dugdale M. ANEMIA. *ObstetGynecolClin North Am*. 2001 Jun 1;28(2):363–82.
36. Haybar H, Pezeshki SMS, Saki N. Evaluation of complete blood count parameters in cardiovascular diseases: An early indicator of prognosis? *ExpMolPathol*. 2019 Oct;110:104267.
37. Danese, E., Lippi, G. and Montagnana, M. (2015). Red blood cell distribution width and cardiovascular diseases. *Journal of Thoracic Disease*, [online] 7(10), pp.E402–E411. doi:<https://doi.org/10.3978/j.issn.2072-1439.2015.10.04>
38. Significance of platelet volume indices and platelet count in ischaemic heart disease - ProQuest [Internet]. [cited 2024 Feb 12]. Available from: <https://www.proquest.com/openview/c8032850cd031a28252a2db38a65295a/1?pq-origsite=gscholar&cbl=2041066>
39. Handtke S, Thiele T. Large and small platelets—(When) do they differ? *J ThrombHaemost*. 2020 Jun 1;18(6):1256–67.
40. Handtke S, Steil L, Palankar R, Conrad J, Cauhan S, Kraus L, et al. Role of Platelet Size Revisited—Function and Protein Composition of Large and Small Platelets. *ThrombHaemost*. 2019 Mar;119(3):407–20.
41. Wolberg AS. Primed to Understand Fibrinogen in Cardiovascular Disease. *ArteriosclerThrombVasc Biol*. 2016 Jan;36(1):4–6.
42. Lin Y, Hu X, Wang W, Yu B, Zhou L, Zhou Y, et al. D-Dimer Is Associated With Coronary Microvascular Dysfunction in Patients With Non-obstructive Coronary Artery Disease and Preserved Ejection Fraction. *Front Cardiovasc Med* [Internet]. 2022 [cited 2024 Feb 22];9. Available from: <https://www.frontiersin.org/articles/10.3389/fcvm.2022.937952>
43. Reihani H, SepehriShamloo A, Keshmiri A. Diagnostic Value of D-Dimer in Acute Myocardial Infarction Among Patients With Suspected Acute Coronary Syndrome. *Cardiol Res*. 2018 Feb;9(1):17–21.
44. Smith, J.K., Krishnan, S., & Wise, D. (2019). Neutrophils in Atherosclerosis: A Review of Mechanisms and Therapeutic Approaches. *Journal of Inflammation Research*, 12, 325–335.

45. Frostegård, J. (2013). Immunity, Atherosclerosis and Cardiovascular Disease. *BMC Medicine*, 11, 117.
46. Swirski, F.K., & Nahrendorf, M. (2013). Leukocyte Behavior in Atherosclerosis, Myocardial Infarction, and Heart Failure. *Science*, 339(6116), 161–166.
47. Jafarzadeh, A., & Nemati, M. (2019). Relevance of Basophils and Eosinophils in Atherosclerosis: From Pathophysiology to Treatment. *Expert Review of Cardiovascular Therapy*, 17(9), 657–666.
48. Libby, P., & Hansson, G.K. (2015). Inflammation and Immunity in Diseases of the Arterial Tree: Players and Layers. *Circulation Research*, 116(2), 307–311.
49. Definition of neutrophil - NCI Dictionary of Cancer Terms - NCI [Internet]. 2011 [cited 2024 Feb 22]. Available from: <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/neutrophil>
50. Malech HL, DeLeo FR, Quinn MT. The Role of Neutrophils in the Immune System: An Overview. *Methods Mol Biol Clifton NJ*. 2014;1124:3–10.
51. Nathan C. Neutrophils and immunity: challenges and opportunities. *Nat Rev Immunol*. 2006 Mar;6(3):173–82.
52. Lymphocyte [Internet]. [cited 2024 Feb 22]. Available from: <https://www.genome.gov/genetics-glossary/Lymphocyte>
53. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Lymphocytes and the Cellular Basis of Adaptive Immunity. In: *Molecular Biology of the Cell* 4th edition [Internet]. Garland Science; 2002 [cited 2024 Feb 22]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK26921/>
54. LeBien TW, Tedder TF. B lymphocytes: how they develop and function. *Blood*. 2008 Sep 1;112(5):1570–80.
55. Fabbri M, Smart C, Pardi R. T lymphocytes. *Int J Biochem Cell Biol*. 2003 Jul 1;35(7):1004–8.
56. Definition of monocyte - NCI Dictionary of Cancer Terms - NCI [Internet]. 2011 [cited 2024 Feb 22]. Available from: <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/monocyte>
57. Ziegler-Heitbrock L. Blood Monocytes and Their Subsets: Established Features and Open Questions. *Front Immunol* [Internet]. 2015 [cited 2024 Feb 22];6. Available from: <https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2015.00423>
58. Espinoza VE, Emmady PD. Histology, Monocytes. In: *StatPearls* [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Feb 22]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK557618/>
59. Kain V, Halade GV. Role of Neutrophils in Ischemic Heart Failure. *PharmacolTher*. 2020 Jan;205:107424.
60. Gaul DS, Stein S, Matter CM. Neutrophils in cardiovascular disease. *Eur Heart J*. 2017 Jun 7;38(22):1702–4.

61. Mehta J, Dinerman J, Mehta P, Saldeen TG, Lawson D, Donnelly WH, et al. Neutrophil function in ischemic heart disease. *Circulation*. 1989 Mar;79(3):549–56.
62. Multiple Roles for Neutrophils in Atherosclerosis | *Circulation Research* [Internet]. [cited 2024 Feb 22]. Available from: <https://www.ahajournals.org/doi/full/10.1161/circresaha.111.257535>
63. Fuchs, T.A., & Brill, A. (2012). Neutrophil Extracellular Trap (NET) Impact on Deep Vein Thrombosis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 32(8), 1777–1783.
64. Violi, F., Loffredo, L., & Carnevale, R. (2017). Ischemic Stroke and Myocardial Infarction: A Role for Oxidative Stress and Antioxidant Agents. *Thrombosis and Haemostasis*, 117(3), 576–584.
65. Johnson, J.L. (2011). Matrix Metalloproteinases in Coronary Artery Disease. *The Future of Biomarkers in Atherosclerosis and Ischemic Heart Disease*, 99–126.
66. Soehnlein, O., & Libby, P. (2020). Targeting Inflammation in Atherosclerosis - From Experimental Insights to the Clinic. *Nature Reviews Drug Discovery*, 20(8), 589–610
67. Role of Lymphocytes in Myocardial Injury, Healing, and Remodeling After Myocardial Infarction | *Circulation Research* [Internet]. [cited 2024 Feb 22]. Available from: <https://www.ahajournals.org/doi/10.1161/circresaha.116.304072>
68. *Frontiers* | The Spectrum of B Cell Functions in Atherosclerotic Cardiovascular Disease [Internet]. [cited 2024 Feb 22]. Available from: <https://www.frontiersin.org/articles/10.3389/fcvm.2022.864602/full>
69. Angkananard T, Anothaisintawee T, McEvoy M, Attia J, Thakkinstian A. Neutrophil Lymphocyte Ratio and Cardiovascular Disease Risk: A Systematic Review and Meta-Analysis. *BioMed Res Int*. 2018;2018:2703518.
70. Núñez J, Miñana G, Bodí V, Núñez E, Sanchis J, Husser O, et al. Low lymphocyte count and cardiovascular diseases. *Curr Med Chem*. 2011;18(21):3226–33.
71. Gusev E, Sarapultsev A. Atherosclerosis and Inflammation: Insights from the Theory of General Pathological Processes. *International Journal of Molecular Sciences*. 2023 Jan;24(9):7910.
72. Shahid F, Lip GYH, Shantsila E. Role of Monocytes in Heart Failure and Atrial Fibrillation. *J Am Heart Assoc*. 7(3):e007849.
73. Nikiforov NG, Kirichenko TV, Kubekina MV, Chegodaev YS, Zhuravlev AD, Ilchuk LA, et al. Macrophages derived from LPS-stimulated monocytes from individuals with subclinical atherosclerosis were characterized by increased pro-inflammatory activity. *Cytokine*. 2023 Dec 1;172:156411.
74. Sager HB, Kessler T, Schunkert H. Monocytes and macrophages in cardiac injury and repair. *J Thorac Dis*. 2017 Mar;9(Suppl 1):S30–5.
75. Williams H, Mack CD, Li SCH, Fletcher JP, Medbury HJ. Nature versus Number: Monocytes in Cardiovascular Disease. *Int J Mol Sci*. 2021 Aug 24;22(17):9119.
76. Gianopoulos I, Daskalopoulou SS. Macrophage profiling in atherosclerosis: understanding the unstable plaque. *Basic Res Cardiol*. 2024 Feb 1;119(1):35–56.

UNDER PEER REVIEW